GRTS News and Press, Gritstone Oncology Inc. From 12/12/19

Thinly traded micro cap Gritstone Oncology ( GRTS -14.6% ) slumps on modestly higher volume in early trade on the heels of preliminary data from early-stages studies evaluating lead candidate GRANITE and candidate #2 SLATE. The results, apparently disappointing investors, were presented ...

- - Preliminary results demonstrate unprecedented levels of primed CD8+ neoantigen-specific cytotoxic T cells and expansion of pre-existing T cells even in low-dose cohorts -- -- Investor conference call and webcast at 8:00 am ET today -- EMERYVILLE, Calif., Dec. 12, 2019 (GLOBE NEW...

EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the executive management team will webcast a revi...

The following slide deck was published by Gritstone Oncology, Inc. in conjunction with this Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

EMERYVILLE, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president ...

Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...

Gritstone Oncology (NASDAQ: GRTS ): Q3 GAAP EPS of -$0.77 misses by $0.13 . More news on: Gritstone Oncology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

EMERYVILLE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported recent business highlights and financial results for ...